ZA Vesoulis, NE Ters, A Foster, SB Trivedi, SM Liao and AM Mathur OBJECTIVE: To identify factors associated with responsiveness to dopamine therapy for hypotension and the relationship to brain injury in a cohort of preterm infants. STUDY DESIGN: The pharmacy database at St Louis Children's Hospital was retrospectively queried to identify infants who (a) were born o 28 weeks gestation between 2012 and 2014, (b) received dopamine and (c) had blood pressure measurements from an umbilical arterial catheter. A control group was constructed from contemporaneous infants who did not receive dopamine. Mean arterial blood pressure (MABP) at baseline, 1 h and 3 h after initiating dopamine were obtained for each dopamine-exposed infant. MABP measurements at matched time points were obtained in the control group. RESULTS: Sixty-nine dopamine-treated and 45 control infants were included. Mean ΔMABP at 3 h was 4.5 ± 6.3 mm of Hg for treated infants vs 1 ± 2.9 for the control. Median dopamine starting dose was 2.5 μg kg − 1 min − 1 . Dopamine-treated infants were less mature and of lower birth weight while also more likely to be intubated at 72 h, diagnosed with intraventricular hemorrhage (IVH) and to die. Failure to respond to dopamine was associated with greater likelihood of developing IVH (odds ratio (OR) 5.8, 95% confidence interval (CI) 1.1-42.3), while a strong response (ΔMABP410 mm Hg) was associated with a reduction in risk of IVH (OR 0.1, 95% CI 0.01-0.8). CONCLUSION: Low-moderate dose dopamine administration results in modest blood pressure improvements. A lack of response to dopamine is associated with a greater risk of IVH, whereas a strong response is associated with a decreased risk. Further research into underlying mechanisms and management strategies is needed.
INTRODUCTION
The diagnosis of hypotension in very preterm infants has long confounded neonatologists. Early studies 1, 2 formed the basis for the now commonly accepted practice 3 of setting the lower acceptable limit of mean arterial blood pressure (MABP) in mm Hg equal to the estimated gestational age (EGA) in weeks. An alternative definition has been proposed, using MABPo30 mm Hg as the threshold, given evidence that the risk of intraventricular hemorrhage (IVH) increases proportionally to the time spent with MABPo30 mm Hg. [4] [5] [6] [7] [8] [9] Given the paucity and heterogeneity of normative data in this very preterm population, there is considerable variance in management of hypotension; 10 approximately 55-82% of infants born before 28 weeks EGA receive some form of therapy for hypotension, generally volume resuscitation and/or vasoactive medications, the most common of which is dopamine. 11, 12 Dopamine, a non-selective adrenergic agonist, has been widely used for the treatment of hypotension in preterm infants for several decades 7, 13, 14 and has been compared with a number of other antihypotensive regiments, demonstrating that dopamine is superior, or at least equivalent, with a more limited side-effect profile. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] However, there is a relative lack of data about isolated use of dopamine in the hypotensive preterm infant. To date, there has been only one trial of dopamine vs placebo, the results of which are limited by small sample size. 26 In this study, we aim to describe (a) clinical factors associated with the use of dopamine in a cohort of very preterm infants in comparison to a contemporaneous control group who was not treated with dopamine, (b) determinants of blood pressure response to dopamine and (c) differences in the incidence of IVH in hypotensive patients who respond vs those who do not respond to dopamine treatment.
METHODS

Subject identification
This study was conducted in the neonatal intensive care unit at St Louis Children's Hospital, a 75-bed, Level IV unit located in an urban setting. The pharmacy database system was queried to identify all admitted infants who were prescribed dopamine infusions between 2012 and 2014. Our general institutional practice is to consider dopamine initiation when either (a) the MABPoEGA in weeks, (b) there is poor urine output (o1 ml kg
) and/or (c) there are clinical signs of poor perfusion (prolonged central capillary refill time, tachycardia). Infants were included if (a) they were born before 28 completed weeks of gestation, (b) a dopamine infusion was started within the first 72 h after birth and (c) they had blood pressure measurements made by umbilical arterial catheter.
A second cohort of infants was developed as a control group. This group consisted of infants who were recruited as a part of a prospective physiological monitoring study conducted at the same site during the same time period. Infants were included if (a) they were born before 28 completed weeks of gestation, (b) a dopamine infusion was not initiated in the first 72 h after birth and (c) they had blood pressure measurements made by umbilical arterial catheter.
Infants were excluded if they received more than one inotropic agent or postnatal corticosteroids during the study window.
The study protocol was reviewed and approved by the Human Research Protection Office at the Washington University School of Medicine.
Data collection
Clinical factors. A comprehensive set of clinical factors were abstracted from the medical chart, including gestational age at birth, sex, race, birth weight, Apgar scores, delivery method, antenatal magnesium sulfate and/or steroid exposure, histological diagnosis of chorioamnionitis, fentanyl exposure in the neonatal period, presence of patent ductus arteriosus requiring treatment, method of respiratory support at 72 h (invasive or non-invasive) and survival to discharge. Severity of illness for each infant was measured using the clinical risk index for babies (CRIB)-II index developed by Parry et al.
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Dopamine data. Postnatal age at infusion start as well as infusion dosage (μg kg − 1 min − 1 ) at the start and end of the study window were recorded for all dopamine-exposed infants. The administration of volume expansion prior to dopamine infusion was also noted.
Blood pressure data. Umbilical arterial lines (3.5 French Argyle single lumen umbilical vessel catheter, Covidien, Mansfield, MA, USA) were placed, shortly after hospital admission, in the high-lying position, located between the sixth and eighth thoracic vertebrae on chest radiograph as per standard clinical practice. Arterial blood pressure was then determined by use of a pressure transducer connected to the patient monitor (Intellivue MP70, Philips Medical, Andover, MA, USA).
For the dopamine-exposed group, MABP values were obtained at the time of dopamine initiation as well as 1 and 3 h after initiation. In order to provide an equivalent comparison, MABP measurements from a similar distribution of postnatal ages were obtained from the control group as well as follow-up measurements at 1 and 3 h after the initial time point.
Neuroimaging data. The presence (or absence) of IVH as well as severity grade was determined from screening cranial ultrasounds performed during the first 3 days of life and a follow-up study performed at 7-10 days of life, which were scored using the standard algorithm outlined by Papile et al.
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Statistical methodology A comparison of perinatal factors was made between those who received dopamine and the control group using the Mann-Whitney U-test for continuous variables and a two-sided Fisher's Exact test for categorical variables. A repeated-measures analysis of variance design was used to examine the effect of time on blood pressure values, both within and between groups.
Predictors of dopamine treatment success (defined as achieving a MABP at 3 h ⩾ EGA in weeks), non-response (defined as MABP at 3 h ⩽ MABP at the start) and super-response (ΔMABP at 3 h 410 mm Hg) were evaluated using binary logistic regression models. The association between dopamine treatment and the development of IVH was assessed using binary logistic regression with the presence or absence of IVH as the outcome while controlling for factors known to be associated with IVH (EGA, birthweight and antenatal corticosteroids 29 ). In all cases, the correlation between predictors was assessed using the variance inflation factor, a measure of the degree of multicollinearity where variance inflation factor 45 is indicative of highly collinear predictors.
Statistical analysis, including descriptive statistics and regression modeling, were conducted using R version 3.2.1 (R Project for Statistical Computing, Vienna, Austria) and Minitab version 17.0 (Minitab, State College, PA, USA).
RESULTS
Descriptive statistics
Between 2012 and 2014, 2318 infants were admitted to the neonatal intensive care unit at St Louis Children's Hospital. Of those, 69/2318 (3%) met the inclusion criteria (o28 weeks gestation at birth with a umbilical arterial catheter and started on dopamine in the first 72 h of life) and comprise the dopamineexposed cohort. During that same time period, 86 premature infants o28 weeks were recruited for a prospective monitoring study and 46/86 (53%) of those infants met these inclusion criteria for the non-exposed control cohort. Descriptive statistics for each group as well as a between-groups comparison is shown in Table 1 . Of note, the dopamine-exposed infants were less likely to be born to mothers with chorioamnionitis (P o0.01), had higher CRIB-II scores (P o 0.01), were more likely to be diagnosed with IVH (P o 0.01) and more likely to die during hospitalization (P = 0.01).
Blood pressure trajectory Approximately 23% of infants in the dopamine-exposed group received a bolus of normal saline prior to initiation of dopamine and the median starting and ending dose of dopamine was 2.5 μg kg − 1 min − 1 . Infants who received dopamine had a lower MABP, when compared with those who did not receive dopamine at the start (24.6 vs 33.8 mm Hg), 1 h later (27.6 vs 33.6 mm Hg) and 3 h later (29.1 vs 34.4 mm Hg) ( Table 2 ). This between-groups difference was statistically significant across all time points (F = 103.78, P o0.01). There was no significant change in blood pressure over the 3-h study window for those infants who did not receive dopamine (F = 0.24, P = 0.79).
As would be expected, there was a significant increase in blood pressure over the course of the 3-h study window in the dopamine-exposed cohort (F = 8.64, P o 0.01). The distribution of blood pressures in the dopamine treatment group gradually shifted, going from the right skewed distribution centered around 24 mm Hg at the start of treatment, as shown in Figure 1a , to the more normal distribution centered around 30 mm Hg at 3 h of treatment, as shown in Figure 1c .
Dopamine treatment success and non-response No factors could be identified that predicted success of dopamine treatment, defined as achieving MABP ⩾ EGA, 3 h after initiation of dopamine (Table 3) . A lower 5-min Apgar score was associated with non-response to dopamine, defined as no change or decrease in blood pressure 3 h after initiation of dopamine infusion (odds ratio (OR) 0.6, 95% confidence interval (CI) 0.4-0.8, Table 3 ).
Dopamine super-response Twenty-one of the 69 dopamine-exposed infants (30%) met the criteria for super-response, defined as ΔMABP410 mm Hg from the baseline 3 h after treatment start. Increasing 5-min Apgar scores (OR 1.6, 95% CI 1.1-2.5), presence of chorioamnionitis (OR 11.4, 95% CI 1.3-102.7) and increasing dopamine dose (OR 2.1, 95% CI 1.2-3.4) were independently associated with an increased likelihood of a super-response to dopamine. Increasing gestational age was associated with a decreased likelihood of developing a super-response (OR 0.5, 95% CI 0.3-0.9). Although statistically significant, the differences in the mean starting Table 4 .
DISCUSSION
Our data confirm that dopamine, at low-to-moderate doses (1-7.5 μg kg
, is effective at increasing the MABP as there is a statistically significant improvement (4.5 ± 6.3 mm Hg) in blood pressure following the first few hours of dopamine treatment in hypotensive preterm infants. This effect is sufficient to halve the proportion of infants with MABP oEGA, from 60% at the treatment start to only 30% at 1 h. Additional treatment time does not increase the likelihood of success.
Although of similar gestational age and birth weight, infants who were treated with dopamine were sicker, as evidenced by higher CRIB-II scores, and were more likely to suffer long-term consequences, in the form of death and IVH, findings in line with a priori expectations. Interestingly, only 60% of infants who received dopamine were hypotensive by the MABP o EGA criteria at the start of treatment. However, given the retrospective nature of the study, it is not possible to intuit the intention behind initiating treatment and may include factors other than the blood pressure.
Many of the factors that are associated with the development of IVH in this study have been noted by other researchers, including antenatal corticosteroids 30 and delivery method 30, 31 as well as opioid exposure. 32, 33 The data in this study reveal a new, previously undescribed association between IVH and the lack of response to dopamine, rather than measured blood pressure at the time of treatment initiation. Although no particular indicators for treatment success could be identified, a more extensive delivery room resuscitation (as indirectly indicated by lower Apgar scores at 5 min) is associated with an increased likelihood of treatment failure. This treatment failure is, in turn, associated with an increased likelihood of developing IVH, suggesting a correlation between the two, although establishing cause and effect is not possible given the retrospective nature of these data.
A dysfunctional cerebrovascular autoregulatory system, which is not able to properly dampen blood pressure fluctuations in a sick, preterm infants may be the common denominator in both instances. Cerebral autoregulation is a complex system and disruption may arise from several causes, including developmental immaturity, hypotension and ischemic injury. Previous work has demonstrated clear differences in the ability to dampen blood pressure fluctuations across gestational ages. 34 Furthermore, Soul et al. 35 and Noori et al., 36 among others, have highlighted this potential vulnerability, implicating altered cerebral autoregulation in the setting of hypotension as a key factor for the pathogenesis of IVH. Indeed, each point increase in the Apgar score is associated with a 40% reduction in the likelihood of dopamine treatment failure, further underscoring the potential role perinatal ischemia may have in autoregulatory dysfunction.
It is difficult to disentangle from these data, however, whether an initial ischemic insult leads to autoregulatory dysfunction and hypotension or whether hypotension itself is the inciting factor, contributing to ischemia and subsequent autoregulatory failure. There is evidence in adults that hypotension exacerbates preexisting autoregulatory failure, 37 although there has been no convincing evidence of the same in the preterm infant population. Regardless, there is likely a strong feedback loop between these factors that exacerbates the initial injury. Nevertheless, it should again be emphasized that the results of this study reflect an association and cannot definitively identify the underlying mechanism.
We also found a decreased use of dopamine in infants who were born to mothers with pathologically confirmed chorioamnionitis. Relative insufficiency of the hypothalamic-pituitaryadrenal axis, which has been described extensively by Watterburg et al. 38 in the context of bronchopulmonary dysplasia, may also provide a unifying mechanism, in the form of adrenergic receptor downregulation, to explain the lack of response to dopamine in some infants. However, the reasons for the decreased use of dopamine in infants born to mothers with chorioamnionitis remain unclear. Cortisol levels were not measured in any of the infants in this study.
Indeed, even among those infants who received dopamine, the subset of infants who displayed a robust response ('superresponders') had a decreased likelihood of developing IVH, suggesting that response to dopamine may serve as a biomarker for the function of the autoregulatory system and the risk for IVH.
Strengths and limitations
Given the nature of medication dispensation at our institution, it is unlikely that any infants who received dopamine were missed, as all dopamine syringes are prepared in the central pharmacy and are done so only after an electronic order has been placed.
Of note, the IVH prediction model did not demonstrate a statistically significant association between rates of IVH and EGA. Although the risk of IVH decreases with advancing maturity, epidemiological data 39 demonstrates significant overlap in the incidence of IVH between infants born at 23 weeks (35% incidence, 95% CI 13-58%) and those born at 28 weeks (12% incidence, 95% CI 9-15%) making it difficult to statistically distinguish differences in a cohort with a relatively tight gestational age distribution such as this one. Furthermore, the regression model included other factors also associated with the development of IVH (birth weight, antenatal steroids, delivery method, sex and race), which likely decreased the impact of EGA on the overall model. There are, however, several limitations to this current study. One major limitation is the use of limited number of fixed time points of blood pressure measurement (as opposed to continuous measurement) and a limited follow-up time period. This study is also limited by its retrospective nature and the potential for introduction of unknown bias. These preliminary findings should be rigorously evaluated in the setting of clinical trial in order to test their validity. Nevertheless, to our knowledge, this report represents the largest report of short-term outcomes in dopamine-exposed preterm infants in comparison to a contemporaneously collected control cohort.
Future directions A recent trial was opened in the EU and the UK (ClinicalTrials.gov NCT01482559) to investigate the impact of dopamine vs placebo with the primary outcome measure of survival to 36 weeks corrected age with severe brain injury and a secondary outcome of survival without moderate or severe long-term neurodevelopmental disability. Collection of primary outcome data is not expected until 2018.
Given the potential implication that hypotension, in association with vasoregulatory and autoregulatory dysfunction, is a contributing factor for brain injury, and thus neurodevelopmental impairment, research should continue in order to better develop a strategy for identifying infants most likely to benefit from treatment, initiating treatment in the appropriate time frame and identifying the target blood pressures for escalation of therapy. Our findings further indicate the urgent need for a randomized controlled trial using continuous blood pressure monitoring, investigation of the hypothalamic-pituitary-adrenal axis and frequent surveillance for IVH. Defined as an increase in MABP410 mm Hg from baseline after 1 h of dopamine treatment.
